Drugs / [225Ac]Ac-FL-020
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06492122 | Aug 2024 → Oct 2026 expected | castration-resistant prostate carcinoma | Full-Life Technologies UK Limited | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | [225Ac]Ac-FL-020 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06492122 ↗ |
| Route | Intravenous | “\[225Ac\]Ac-FL-020 injected intravenously” NCT06492122 ↗ |